Pfizer Inc. 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 3, 2005, and the six-month period ended on the same date. Pfizer Inc. is a global research-based pharmaceutical company operating in Human Health, Consumer Healthcare, and Animal Health segments. The reporting period included three additional business days compared to the same period in 2004.
Key Financial Metrics
| Metric (Millions USD) | 3 Months Ended July 3, 2005 | 6 Months Ended July 3, 2005 |
|---|---|---|
| Revenues | $12,425 | $25,516 |
| Net Income | $3,463 | $3,763 |
| Diluted EPS | $0.47 | $0.51 |
| Operating Cash Flow | N/A | $6,983 |
| Cost of Sales Margin | 16.7% | 16.7% |
| Total Debt | $12,778 | $12,778 |
| Cash & Short-term Investments | $14,569 | $14,569 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 1% in the quarter and 3% year-to-date compared to 2004, driven by strong performance in Lipitor, Zithromax, and a weakening U.S. dollar, partially offset by declines in COX-2 products and generic competition.
- Profitability: Net income increased 21% in the quarter but decreased 28% year-to-date. The year-to-date decline is primarily due to a $1.7 billion income tax charge related to the repatriation of foreign earnings and a $1.2 billion charge associated with the suspension of Bextra sales.
- Cost Structure: Cost of sales increased 19% in the quarter and 20% year-to-date, rising as a percentage of revenue due to product mix changes and Bextra-related inventory write-offs.
- Balance Sheet: Total assets decreased from $123.7 billion to $112.3 billion, largely due to a reduction in short-term investments used to fund the repatriation of foreign earnings and debt repayments.
Guidance, Outlook, and Risks
Outlook: Management expects full-year 2005 revenues to evidence a modest decline relative to 2004 due to the strengthening U.S. dollar and patent expirations. Targeted 2005 Adjusted Income is approximately $14.6 billion, with reported Net Income expected to be approximately $9.1 billion (diluted EPS of $1.24).
Key Initiatives: The "Adapting to Scale" productivity initiative is underway, with expected total costs of $4–5 billion through 2008, targeting $4 billion in annual cost savings by 2008.
Risks and Contingencies:
- Bextra Suspension: Pfizer recorded $1.2 billion in charges (including $1.1 billion in asset impairment) following the FDA's request to suspend Bextra sales due to skin reaction risks.
- Patent Expirations: Significant revenue impacts are expected from the loss of exclusivity for Zithromax (Nov 2005), Zoloft (2006), and Norvasc/Zyrtec (2007).
- Tax Repatriation: A $1.7 billion tax charge was recorded for repatriating $36.7 billion in foreign earnings under the American Jobs Creation Act of 2004.
- Legal Proceedings: Ongoing litigation includes product liability claims related to Celebrex and Bextra, patent challenges for Neurontin, and environmental settlements.
Investor Verification Checklist
- Verify the impact of the $1.7 billion tax charge on the effective tax rate and future cash flows.
- Monitor the trajectory of Bextra-related charges and the potential for further regulatory actions on COX-2 inhibitors.
- Assess the progress of the "Adapting to Scale" initiative and its ability to deliver projected $4 billion in annual savings.
- Review the timeline and financial impact of upcoming patent expirations for Zithromax, Zoloft, and Norvasc.
- Confirm the status of the $5 billion share repurchase program authorized in June 2005.